Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index f...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 515 3185

Fax: 650 351 0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

winners18 Jan. 13 at 11:49 PM

$CTMX big picture

1 · Reply

Determinedstocks Jan. 12 at 8:46 PM

$CTMX crawling back into the green

0 · Reply

Selfmademan Jan. 12 at 6:46 PM

$CTMX kinda like $MGNX except ctmx keeps their best asset(s) to themselves. Mgnx gave away Tzield & Zynyz for peanuts. Varseta-M will go to someone else but peanuts wont be on the menu.

0 · Reply

Turdsniffer Jan. 12 at 3:05 PM

$CTMX early Monday morning high volume dumpathon 😐😏

1 · Reply

Caudaldeorotriple Jan. 11 at 4:13 PM

$CTMX

0 · Reply

Dubbyy Jan. 9 at 1:58 PM

$CTMX Check out this article from TipRanks | CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target | https://tipranks.onelink.me/WJho/9g0vusvw

0 · Reply

AxiomX Jan. 9 at 11:53 AM

$CTMX Ready for the big bounce!!!

0 · Reply

Selfmademan Jan. 9 at 10:18 AM

$CTMX ah took little profits i could from omer and got back i here. No more getting out of this stock by me until multi billion valuation. Too risky to stay out of a company that might have one of the best ADC`s ever and so close to readout.

1 · Reply

winners3628 Jan. 9 at 7:47 AM

$CTMX 108 pts on immu132 approval.IMMU-132, known as sacituzumab govitecan (brand name Trodelvy), received Breakthrough Therapy Designation (BTD) from the FDA in 2016 for metastatic triple-negative breast cancer (mTNBC), a significant FDA recognition for potentially better treatments. This

0 · Reply

winners3628 Jan. 9 at 7:43 AM

$CTMX https://www.nejm.org/doi/full/10.1056/NEJMoa1814213

0 · Reply

CytomX Therapeutics Announces Business Update and Company Milestones for 2026

Dec 15, 2025, 1:46 AM EST - 4 weeks ago

CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling

Nov 25, 2025, 8:00 AM EST - 7 weeks ago

CytomX Therapeutics to Present at Upcoming December Investor Conferences

Nov 18, 2025, 9:32 AM EST - 2 months ago

CytomX Therapeutics: Leaning Into The Hype, But What's Next?

Nov 13, 2025, 8:00 AM EST - 2 months ago

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 11, 2025, 4:04 AM EST - 2 months ago

Targeting Adhesion Molecules With ADC's: The Bet Of CytomX

Nov 7, 2025, 2:26 PM EST - 2 months ago

CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:10 PM EST - 2 months ago

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 3:15 PM EST - 2 months ago

Top Biotech Stocks Riding The Rally

GRAL GRFS INCY

Nov 4, 2025, 9:15 AM EST - 2 months ago

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2025, 8:00 AM EDT - 2 months ago

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 20, 2025, 4:05 PM EDT - 3 months ago

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

Oct 13, 2025, 11:45 PM EDT - 3 months ago

CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible

Oct 12, 2025, 5:00 AM EDT - 3 months ago

Renewed Tariff Fears Spotlight Top Performing Stocks Since April

COMM NVDA PSIX SMH VSAT

Oct 6, 2025, 11:20 AM EDT - 3 months ago

CytomX: A Fresh Start With New Drugs After Total Pipeline Failure

Sep 10, 2025, 4:26 PM EDT - 4 months ago

CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 8:00 AM EDT - 4 months ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Aug 13, 2025, 8:00 AM EDT - 5 months ago

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

Aug 8, 2025, 6:10 PM EDT - 5 months ago

CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 5:05 PM EDT - 5 months ago

CytomX Therapeutics: Updated Outlook For Late 2025

Aug 7, 2025, 4:10 PM EDT - 5 months ago

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 5 months ago

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

May 29, 2025, 8:00 AM EDT - 8 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 8 months ago

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

May 13, 2025, 10:34 AM EDT - 8 months ago

CytomX Therapeutics: Doubling Overnight On Phase 1 Data

May 12, 2025, 2:40 PM EDT - 8 months ago

CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

May 12, 2025, 11:11 AM EDT - 8 months ago

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

May 12, 2025, 6:50 AM EDT - 8 months ago

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

May 12, 2025, 6:15 AM EDT - 8 months ago

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

May 12, 2025, 6:15 AM EDT - 8 months ago

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:00 AM EDT - 9 months ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 28, 2025, 4:00 PM EDT - 9 months ago

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

Mar 6, 2025, 6:34 PM EST - 11 months ago

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:10 PM EST - 11 months ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 11 months ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 11 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Jan 6, 2025, 4:05 PM EST - 1 year ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Nov 27, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 8:44 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:10 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Aug 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 17, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

May 16, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces New Employment Inducement Grants

May 9, 2024, 9:10 AM EDT - 1 year ago

CytomX stock down 30% despite encouraging cancer study results

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 7, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 1, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

winners18 Jan. 13 at 11:49 PM

$CTMX big picture

1 · Reply

Determinedstocks Jan. 12 at 8:46 PM

$CTMX crawling back into the green

0 · Reply

Selfmademan Jan. 12 at 6:46 PM

$CTMX kinda like $MGNX except ctmx keeps their best asset(s) to themselves. Mgnx gave away Tzield & Zynyz for peanuts. Varseta-M will go to someone else but peanuts wont be on the menu.

0 · Reply

Turdsniffer Jan. 12 at 3:05 PM

$CTMX early Monday morning high volume dumpathon 😐😏

1 · Reply

Caudaldeorotriple Jan. 11 at 4:13 PM

$CTMX

0 · Reply

Dubbyy Jan. 9 at 1:58 PM

0 · Reply

AxiomX Jan. 9 at 11:53 AM

$CTMX Ready for the big bounce!!!

0 · Reply

Selfmademan Jan. 9 at 10:18 AM

1 · Reply

winners3628 Jan. 9 at 7:47 AM

0 · Reply

winners3628 Jan. 9 at 7:43 AM

$CTMX https://www.nejm.org/doi/full/10.1056/NEJMoa1814213

0 · Reply

winners3628 Jan. 9 at 7:39 AM

$CTMX shares price would be btw $100 to 200 per shares .It depends on how many dilutions to raise money for the trial.

0 · Reply

winners3628 Jan. 9 at 7:33 AM

$CTMX gild paid 21 billions to acquire immu after tnbc indication approval which is a much smaller market compare to colon cancer. Currenty ctmx has enrolled 100 pts on 3 different therapeutic doses .Are those data good enough for approval? Immu got approval on 150 pts. 3 yrs timeframe to get to 21 billions market cap for ctmx to run the pivotal if fda wants to more pts data.

0 · Reply

Turdsniffer Jan. 8 at 5:47 PM

$CTMX will probably hit 4.05 - 4.10 and then we steady climb past 52 week high over the next month

0 · Reply

Mavi93 Jan. 8 at 4:48 PM

$CTMX The Path to Happiness

0 · Reply

Determinedstocks Jan. 8 at 3:54 PM

$CTMX If I'm reading this press release correctly, there seems to be a lot of activity for CX-2051 - read out on up to 100 patients Q1/2026, a potential registrational study design in 2026, testing Varesta-M with another drug starting Q1/2026, and testing additional indications in 2H/2026. That doesn't include the work being do in CX-801. Seems like actions you'd take when you've got something good on your hands. They're not abandoning their therapy, seems like they're doubling down on it.

0 · Reply

DARKP00L Jan. 8 at 1:47 PM

$CTMX 08:17 on Jan. 08 2026 CytomX Therapeutics Announces CX-2051 Phase 1 Colorectal Cancer Expansion Data On Track For Q1 2026; Varseta-M Phase 1 Combination Study With Bevacizumab In Colorectal Cancer To Start In Q1 2026 With Initial Data Expected By H1 2027 #tradeideas

0 · Reply

S_Franconi Jan. 8 at 1:33 PM

$CTMX CytomX Therapeutics Announces Business Update and Company Milestones for 2026 https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-business-update-and-company

0 · Reply

DanilaMaster Jan. 8 at 1:29 PM

$CTMX very, very positive and excited for 2026 - CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th -

0 · Reply

winners3628 Jan. 8 at 1:24 PM

$CTMX awefull quiet! Abbv take over? Abbv acquired imgn 2 yrs ago!

0 · Reply

bryantboy99 Jan. 8 at 1:22 PM

$CTMX you've got mail. https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-business-update-and-company

0 · Reply

DaBullRunner Jan. 8 at 2:16 AM

$CTMX $IMRX bang and bang👇💰💰💰 🚨BFRG🚨is my next BIG pay day ⏳

2 · Reply

Dubbyy Jan. 8 at 12:04 AM

$CTMX https://uk.finance.yahoo.com/news/piper-sandler-h-c-wainwright-094511865.html

1 · Reply

Market Cap	735.35M
Revenue (ttm)	138.10M
Net Income (ttm)	31.87M
EPS (ttm)	N/A
PE Ratio	10.88
Forward PE	N/A
Profit Margin	23.08%
Debt to Equity Ratio	0.00

Volume	1,613,400
Avg Vol	3,053,458
Day's Range	N/A - N/A
Shares Out	169.44M
Stochastic %K	16%
Beta	2.42
Analysts	Strong Sell
Price Target	$7.07